Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11023368 | 0.98 | HPGD (0.56) | HPGDHTTGPR84MAPTNPSR1 | |
| SCHEMBL30372303 | 0.85 | GPR35 (0.48) | GPR84MAPTNPSR1DAOPTGS2 | |
| SCHEMBL6695308 | 0.84 | ALDH1A1 (0.51) | HPGDHTTGPR84MAPTNPSR1 | |
| SCHEMBL15177362 | 0.83 | MAPT (0.61) | HPGDGPR84MAPTNPSR1DAO | |
| SCHEMBL11024967 | 0.83 | DAO (0.58) | GPR84MAPTDAOPTGS2ALDH1A1 | |
| SCHEMBL11453552 | 0.83 | MAPT (0.61) | HPGDGPR84MAPTNPSR1DAO | |
| SCHEMBL11718951 | 0.83 | DAO (0.58) | GPR84MAPTDAOPTGS2ALDH1A1 | |
| SCHEMBL2490471 | 0.83 | DAO (0.58) | GPR84MAPTDAOPTGS2ALDH1A1 | |
| SCHEMBL6691497 | 0.83 | ALDH1A1 (0.50) | HPGDHTTGPR84MAPTNPSR1 | |
| SCHEMBL586684 | 0.82 | PTGS2 (0.43) | HPGDHTTPTGS2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534700-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050014816-A1 | Thiophene amino acid derivatives, process for preparing them and pharmaceutical compositions containing them | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050014817-A1 | Fluorothiophene derivatives, process for preparing them and pharmaceutical compositions containing them | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2005003114-A1 | 5-FLUORO-THIOPEN-COMPOUNDS,THE PROCESS FOR THEIR PREPARATION,THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS METALLOPOTENASES INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003115-A1 | THIOPHENE AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1493739-A1 | Thiophene derivatives of aminoacids, process for the preparation thereof and compositions containing them | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1493740-A1 | 5-fluoro-thiophene compounds, the process for their prepartion, the pharmaceutical compositions containing them and their use as metalloproteinases inhibitors | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014817-A1 | Fluorothiophene derivatives, process for preparing them and pharmaceutical compositions containing them | MMP12, MMP13, MMP11 | HPGD 884/4885HTT 3756/4885GPR84 921/4885 |
| US-20050014816-A1 | Thiophene amino acid derivatives, process for preparing them and pharmaceutical compositions containing them | MMP12, MMP9, MMP13 | HPGD 1976/4885HTT 4087/4885GPR84 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.